Enrolment
Active
Credential verified
Pending Requests
3
Awaiting approval
Consents Given
14
+2 this month
Risk Level
Medium
1 high-risk pending
Biometric Verification Required
1 high-risk financial request is blocked pending genomic biometric enrolment.
Your account is flagged High Risk: transaction over £50,000 from an unverified institution. CarePass requires genomic ZKP verification before approval.
Pending Consent Requests
Approve or decline access to your data
Pending Consent Requests
All organisations requesting access to your data
Consent History
Full audit trail with timestamps
| Organisation | Type | Data Scope | Decision | Verification | Date |
|---|
My Clinical Record
Longitudinal care summary linked to consent and identity controls
Record Status
Synced
NHS spine linked
Last Update
27 Jun
09:18 BST
Data Sources
4
OUH, GP, lab, pharmacy
Active Care Plans
2
Oncology + prevention
Care Summary
Verified clinical profile
NHS Number
943 476 5910
Lead Clinician
Dr Maya Patel
Primary Site
Oxford University Hospitals
Care Pathway
Oncology surveillance
Recent Encounters
Last 90 days
Oncology review
22 Jun 2026Stable surveillance status. Follow-up cfDNA panel booked for July.
cfDNA methylation panel
10 Jun 2026SEPT9 signal remains above baseline; clinical review completed.
Primary care bloods
21 May 2026HbA1c and renal function in range. Lipid trend reviewed.
Medication and Alerts
Atorvastatin 20mg
Once nightly - active prescription
Immunotherapy monitoring
Response markers tracked quarterly
No known drug allergies
Last reconciled 22 Jun 2026
Latest Results
HbA1c5.4%
LDL cholesterol2.7 mmol/L
cfDNA SEPT9Elevated
Clinical Documents
My Genomic Identity
Cryptographic credential — no raw DNA stored or transmitted
CarePass Credential
GID-4829-OXFD-7721
James Chen
Verified
Oxford CLIA
ZKP Protocol
Groth16 / XRPL
Enrolled
12 May 2026
Next Review
12 May 2028
Hash
0x4f2a...c8d1
Privacy Architecture
Zero-Knowledge Proof system
Saliva to Hash Only
Raw DNA never leaves the CLIA lab — only a ZKP hash is stored.
Prove Without Revealing
Verifiers confirm identity without seeing your genome sequence.
On-Chain Anchor
Proof hash anchored to XRP Ledger — tamper-proof and auditable.
Transaction Risk Policy
Determines when biometric re-verification is triggered
Low Risk
Clinical data sharing with NHS, academic opt-in
PIN onlyMedium Risk
Financial transactions under £50k, pharma licensing
Face + PINHigh Risk
Transactions over £50k, unverified requestors
Genomic ZKPBiometric Enrolment
Required to unlock high-risk transaction approval
1
Order Saliva Kit
Self-collection kit
Oragene OG-600 kit dispatched 8 Jun 2026, received at Oxford CLIA Lab 10 Jun 2026.
Kit ReceivedOX-48291-K
2
Lab Processing
WGS at Oxford CLIA facility
Germline DNA extracted, WGS complete (30x coverage). Groth16 ZKP hash generated. Raw sequence permanently destroyed.
Hash Generated30x WGSRaw data: Destroyed
3
Activate Credential
Bind ZKP to this session
Activate your genomic credential. Future high-risk transactions will use your ZKP automatically.
Initialising...
Why is this Required?
1 Blocked Transaction
Financial request from Meridian Capital Partners (£120,000) is blocked pending biometric verification.
CarePass requires genomic verification for transactions exceeding risk thresholds — protecting against synthetic identity fraud.
Privacy Guarantees
Face scan processed on-device only
Raw DNA never leaves CLIA lab
ZKP reveals uniqueness only — no health data disclosed
GDPR Article 9 explicit consent on file
Data Preferences
Control what organisations can access and under what conditions
Clinical Data Sharing
NHS trusts and academic partners
Immunotherapy Response Data
cfDNA methylation and mutation profiles
Treatment History
Oncology records and response monitoring
Pathology Reports
Biopsy and histopathology results
Genomic Health Report
Pharmacogenomics and germline variants
Transaction Identity
Financial and verification use cases
Allow Financial Verification
Banks and fintechs verify via ZKP
Auto-approve Low-Risk
Trusted organisations skip manual approval
Biometric Gate for High Risk
ZKP required for transactions over £50k
Research and Data Licensing
Opt-in pharma and population health
Anonymised Cohort Contribution
Licensed pharma research — 50 GenoPoints per month
Return of Actionable Findings
Receive clinically relevant research discoveries
Commercial Research Access
Pharmaceutical companies (anonymised, GDPR Art. 9)
Notifications
How you are informed of new requests
Push Notifications
Instant alerts for new consent requests
Email Digest
Weekly summary of all consent activity
High-Risk SMS Alert
Immediate SMS and push for high-risk requests
Redeemable Health Services
Use CarePass Health Credits for prevention, screening, and clinical support
Health Credits
840
+80 this month
Available Services
6
Ready to redeem
Next Eligible Screen
Jul
cfDNA panel
Unlocked Reports
2
Genomics + dashboard
Redeemable Health Services
CarePass Health Credits: 840 pts
🧬
Annual cfDNA Screen
Full liquid biopsy panel — cancer methylation + mutation
500 pts
💊
Pharmacogenomics Report
Drug metabolism panel for 120+ medications
200 pts
👨👩👧
Family Sequencing Voucher
50% off whole-genome sequencing for one family member
350 pts
🏃
NHS Prescription Discount
10% off 3-month NHS prescription charge
100 pts
🔬
Trial Priority Access
Fast-track enrolment for matched clinical trials
150 pts
📊
Immunotherapy Dashboard
12-month longitudinal biomarker trend visualisation
80 pts
Health Risks from Clinical Records
Signals derived from longitudinal clinical data and genomic biomarkers
Clinical Signals
4
Updated from records
Elevated Risk
1
Follow-up advised
Moderate Risk
2
Monitor trend
Low Risk
1
Stable marker
Health Risks from Clinical Records
Clinical decision support
Derived from cfDNA methylation patterns and longitudinal clinical data. Consult your GP before acting on these signals.
Colorectal Cancer Risk
ElevatedcfDNA SEPT9 methylation above 99th population percentile. Confirmed by 3 sequential blood draws.
Population avgYour risk: 78th–94th percentile
Cardiovascular Risk Score
ModerateQRISK3 polygenic score + lipid panel trend. Mild upward trajectory over 18 months.
Population avgYour risk: 52nd percentile
Immunotherapy Response Likelihood
IntermediateTotiomics IMMUNO-PREDICT v2.1 model. TMB-H but PD-L1 TPS 15–49%. Mixed response probability.
Non-responderStrong responder
Type 2 Diabetes Risk
LowHbA1c stable. Polygenic risk score 12th percentile. No methylation signal at TCF7L2 locus.
Population avgYour risk: 18th percentile
14
Papers Published
£342
Data Dividends Earned
£120
Tax Credit Available
4
Research Partners
Data Dividends
+£18 this month
Total earned£342.00
Pending payout£18.40
Next payout1 Jul 2026
Tax Credit Certificate
FY 2025–26
Your genomic data contributions qualify under HMRC Health Data Research Relief. The certificate below can be submitted with your Self Assessment return.
Qualifying contributions12 events
Assessed data value£1,200.00
Relief rate10%
Tax credit claimable£120.00
Research Published Using Your Data
14 papers
Your anonymised data contributed to the following peer-reviewed publications, acknowledged in the supplementary data appendix.
cfDNA Methylation as a Pan-Cancer Early Detection Biomarker in a Multi-Ethnic UK Cohort
2026Nature Medicine · Oxford NHS / Totiomics · n=12,400
cfDNAEarly Detection
Zero-Knowledge Proof Genomic Identity Verification: Clinical Deployment Feasibility
2026npj Digital Medicine · University of Oxford · n=3,200
IdentityZKP
Polygenic Risk Score Integration with Liquid Biopsy for Immunotherapy Response Stratification
2025Cancer Cell · AstraZeneca / CRUK · n=8,750
ImmunotherapyPGS
SEPT9 Hypermethylation as a Blood-Based Colorectal Cancer Surveillance Marker: A 3-Year Longitudinal Study
2025Gut · Oxford University Hospitals · n=2,180
ColorectalLongitudinal